Moderna (MRNA) Advances While Market Declines: Some Information for Investors
Moderna (MRNA) ended the recent trading session at $25.90, demonstrating a +1.97% change from the preceding day's closing price. This change outpaced the S&P 500's 0.22% loss on the day. Elsewhere, the Dow saw an upswing of 0.08%, while the tech-heavy Nasdaq depreciated by 0.51%.
Coming into today, shares of the biotechnology company had lost 4.94% in the past month. In that same time, the Medical sector gained 0%, while the S&P 500 gained 0.45%.
Market participants will be closely following the financial results of Moderna in its upcoming release. It is anticipated that the company will report an EPS of -$2.97, marking a 10.81% rise compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $130.15 million, down 46% from the year-ago period.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$9.81 per share and a revenue of $2.08 billion, indicating changes of -10.6% and -35.83%, respectively, from the former year.
It is also important to note the recent changes to analyst estimates for Moderna. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.89% higher. As of now, Moderna holds a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 87, this industry ranks in the top 36% of all industries, numbering over 250.
The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow MRNA in the coming trading sessions, be sure to utilize Zacks.com.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
32 minutes ago
- Bloomberg
Fed's Daly Says Central Bank Communication Should Be Flexible
Federal Reserve Bank of San Francisco President Mary Daly said central bankers need to communicate with flexibility at times of uncertainty, given that using strong forward guidance sometimes 'comes with a price.' 'The economy is dynamic, and our communications must match it,' Daly said Sunday in a speech prepared for the Western Economic Association International's 100th Annual Conference. Daly didn't comment on the outlook for the economy or policy in her written remarks, which she also said were not about the Fed's ongoing framework review.
Yahoo
37 minutes ago
- Yahoo
AppLovin (NasdaqGS:APP) Reports Robust Q1 Earnings Despite Price Dip Over Last Quarter
AppLovin reported robust Q1 earnings with sales growth and improved net income, yet it faced a 4% share price decline over the last quarter. The price move contrasts with the broader market's flat performance but can be partly attributed to the substantial goodwill impairment and the securities class action lawsuit filed against the company. Despite these challenges, the ongoing share repurchase program and strategic advancements like Chartboost's new capabilities on the MAX platform may have cushioned the impact. Meanwhile, impending board changes and M&A discussions could introduce new dynamics for the company's future trajectory. AppLovin has 3 warning signs we think you should know about. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. The recent developments surrounding AppLovin, including the goodwill impairment and class action lawsuit, may introduce uncertainties that weigh on investor sentiment. While these challenges could pressure the company's revenue and earnings forecasts in the short term, the ongoing share repurchase program and strategic investments in AI and global advertising might support long-term growth trajectories. Over a three-year period, AppLovin's total shareholder return was very large, showcasing its resilience and potential for significant value creation. Despite a recent 4% share price decline, the company's one-year performance exceeded the US Software industry's 16.8% return, indicating robust comparative growth. With a current share price of US$304.62 and analysts' price target of US$432.90, the stock remains at a substantial discount, suggesting potential for future appreciation if the company meets earnings projections. Gain insights into AppLovin's historical outcomes by reviewing our past performance report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGS:APP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
TechCrunch
37 minutes ago
- TechCrunch
Moratorium on state AI regulation clears Senate hurdle
A Republican effort to prevent states from enforcing their own AI regulations cleared a key procedural hurdle on Saturday. The rule, as reportedly rewritten by Senate Commerce Chair Ted Cruz in an attempt to comply with budgetary rules, would withhold federal broadband funding from states if they try to enforce AI regulations in the next 10 years. And the rewrite seems to have passed muster, with the Senate Parliamentarian now ruling that the provision is not subject to the so-called Byrd rule — so it can be included in Republicans' 'One Big, Beautiful Bill' and passed with a simple majority, without potentially getting blocked by a filibuster, and without requiring support from Senate Democrats. However, it's not clear how many Republicans will support the moratorium. For example, Republican Senator Marsha Blackburn of Tennessee recently said, 'We do not need a moratorium that would prohibit our states from stepping up and protecting citizens in their state.' And while the House of Representatives already passed a version of the bill that included a moratorium on AI regulation, far-right Representative Marjorie Taylor Greene subbsequently declared that she is 'adamantly OPPOSED' the provision as 'a violation of state rights' and said it needs to be 'stripped out in the Senate.' House Speaker Mike Johnson defended the provision by saying it had President Donald Trump's support and arguing, 'We have to be careful not to have 50 different states regulating AI, because it has national security implications, right?' In a recent report, Americans for Responsible Innovation (an advocacy group for AI regulation), wrote that 'the proposal's broad language could potentially sweep away a wide range of public interest state legislation regulating AI and other algorithmic-based technologies, creating a regulatory vacuum across multiple technology policy domains without offering federal alternatives to replace the eliminated state-level guardrails.' Techcrunch event Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Save $200+ on your TechCrunch All Stage pass Build smarter. Scale faster. Connect deeper. Join visionaries from Precursor Ventures, NEA, Index Ventures, Underscore VC, and beyond for a day packed with strategies, workshops, and meaningful connections. Boston, MA | REGISTER NOW A number of states do seem to be taking steps toward AI regulation. In California, Governor Gavin Newsom vetoed a high-profile AI safety bill last year while signing a number of less controversial regulations around issues like privacy and deepfakes. In New York, an AI safety bill passed by state lawmakers is awaiting Governor Kathy Hochul's signature. And Utah has passed its own regulations around AI transparency.
